Finance News – Ozempic
What is your interest today?
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
Meta shares fall on AI restructuring report, while Lilly shrugs off Novo's Ozempic price move
Meta’s stock declined following news of changes in its AI division, whereas Eli Lilly’s shares remained steady despite Novo Nordisk’s adjustment of Ozempic pricing impacting the ma...
Read Full Article →Novo Nordisk halves US price of Ozempic
The Danish pharmaceutical company’s stock increased after reducing the cost of its leading medication in the US market, potentially improving access for uninsured individuals manag...
Read Full Article →Half-off Ozempic deal sends Novo Nordisk stock surging
The recent approval for Novo Nordisk’s Wegovy drug in liver treatment, combined with a major discount on Ozempic, has led to a notable increase in the company’s market value.
Read Full Article →Ozempic sales surge as priced-out Mounjaro patients seek cheaper alternative
The substantial increase in Mounjaro’s cost has driven many patients to switch to Ozempic, resulting in a significant boost in its revenue within the competitive weight loss medica...
Read Full Article →Weight-loss drugs may be covered by Medicare, Medicaid under experimental program
The experimental program could potentially reduce out-of-pocket expenses for patients by allowing Medicare and Medicaid to cover expensive GLP-1 medications used for weight managem...
Read Full Article →Novo Nordisk shares plunge 23% on profit warning amid US weight-loss drug competition
The company experienced a significant decline in market value following a reduced profit forecast, reflecting increased challenges in the competitive landscape of weight-loss medic...
Read Full Article →Novo Nordisk issues profit warning as competition — legal and otherwise — hits Wegovy, Ozempic
Novo Nordisk lowered its forecast due to increasing challenges from various competitors, leading to a decline in its stock value and signaling potential impacts on the company's fu...
Read Full Article →The weight loss drug boom has barely begun. How big can it get?
The rising popularity of GLP-1 medications, including Ozempic, positions them to generate substantial revenue, potentially surpassing established blockbuster drugs like statins in...
Read Full Article →A $250 mistake seems set to cost Ozempic maker Novo Nordisk billions
Novo Nordisk is expected to face substantial financial losses as Canada prepares to introduce generic alternatives of its weight loss medication due to the company’s failure to mai...
Read Full Article →Healthy Returns: Ozempic, Wegovy linked to rare cases of serious eye condition
Novo Nordisk’s medications associated with uncommon but severe eye issues may impact the company’s valuation, as emerging health technology firms continue to gain significant inves...
Read Full Article →Activist hedge fund builds stake in Ozempic-maker Novo Nordisk
An investment firm has increased its holdings in the Danish pharmaceutical company known for its diabetes treatment, signaling confidence amid leadership changes and recent decline...
Read Full Article →How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Despite its initial leadership in the growing weight loss medication sector, Novo Nordisk has recently experienced a decline in market share compared to Eli Lilly, affecting its fi...
Read Full Article →Ozempic-maker Novo Nordisk ousts CEO after shares plummet
Novo Nordisk's decision to replace its CEO follows a significant decline in the company’s stock value, underscoring the financial impact of recent market challenges on the pharmace...
Read Full Article →Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year
Novo Nordisk announced that its CEO, Lars Fruergaard Jørgensen, will resign following a significant decline in the company’s market value linked to challenges faced by its key diab...
Read Full Article →Ozempic maker Novo Nordisk boots CEO over stock-price fall
The departure of Novo Nordisk's CEO follows a decline in the company's market value, highlighting investor concerns about future financial performance in the competitive pharmaceut...
Read Full Article →Weight Watchers goes bankrupt even as it tries to ride the Ozempic boom
WeightWatchers has filed for bankruptcy due to over $1 billion in debt, aiming to restructure its finances while shifting focus toward weight loss medications such as GLP-1 treatme...
Read Full Article →